This website is part of the TOBIG Foundation
Menu
close

References

  1. Hofmann et al. ‘Autologous iliac bone graft compared with biphasic hydroxyapatite and calcium sulfate cement for the treatment of bone defects in tibial plateau fractures: A prospective, randomized, open-label, multicenter study’. J Bone Joint Surg Am. 2020;102(3):179-193.
  2. Aljawadi et al. ‘Adjuvant local antibiotic hydroxyapatite bio-composite in the management of open Gustilo Anderson IIIB fractures. Prospective review of 80 patients from the Manchester Ortho-Plastic Unit.’ J Orthop. 2020;18:261–266.
  3. McNally et al. ‘Single-stage treatment of chronic osteomyelitis with a new absorbable, gentamicin-loaded, calcium sulphate/hydroxyapatite biocomposite: a prospective series of 100 cases.’ Bone Joint J. 2016 Sep;98-B(9):1289-96.
  4. Ferguson et al. ‘Radiographic and histological analysis of a synthetic bone graft substitute eluting gentamicin in the treatment of chronic osteomyelitis.’ J Bone Joint Infect. 2019;4:76-84.
  5. Drampalos et al. ‘Augmented debridement for implant related chronic osteomyelitis with an absorbable, gentamycin loaded calcium sulfate/hydroxyapatite biocomposite.’ J Orthop. 2020;17:173-179.
  6. Niazi et al. ‘Adjuvant antibiotic loaded bio composite in the management of diabetic foot osteomyelitis - A multicentre study’. Foot (Edinb). 2019;39:22-27.
  7. Ferguson et al. ‘Ceramic biocomposites as biodegradable antibiotic carriers in the treatment of bone infections’. J Bone Joint Infect. 2017;2(1):38-51.
  8. Ferguson et al. ‘A retrospective cohort study comparing clinical outcomes and healthcare resource utilisation in patients undergoing surgery for osteomyelitis in England: a case for reorganising orthopaedic infection services.’ J Bone Joint Infect. 2021;6:151-163.
  9. Hettwer et al. ‘Establishment and effects of allograft and synthetic bone graft substitute treatment of a critical size metaphyseal bone defect model in the sheep femur’. APMIS. 2019;127:53–63.
  10. Ferguson et al. ‘Not all ceramic antibiotic carriers are the same: outcomes for two different local antibiotic carriers in the management of chronic osteomyelitis.’ Orthop. Proc. 100-B(SUPP_17):46.
  11. Stravinskas et al. ‘Pharmacokinetics of gentamicin eluted from a regenerating bone graft substitute - In vitro and clinical release studies’. Bone Joint Res 2016;5:427–435.
  12. Stravinskas et al. ‘Antibiotic containing bone substitute in major hip surgery: A long term gentamicin elution study’. J Bone Jt Infect.2018;3(2):68-72.
  13. Stravinskas et al. ‘Vancomycin elution from a biphasic ceramic bone substitute.’ Bone Joint Res 2019;8:49–54.
  14. Colding-Rasmussen et al. ‘In-vivo and in-vitro evaluation of vancomycin and gentamicin elution from bone graft substitutes’, European Bone and Joint Infection Society (EBJIS) 35th Annual Meeting, Oxford, UK, September 2016.
  15. EUCAST clinical breakpoints: https://www.eucast.org/clinical_breakpoints/